Tango Therapeutics’ (TNGX) Sees Cautious Analyst Optimism Following Earnings

Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 11 Best Day Trading Stocks to Buy Now.

Financial firm Mizuho raised its share price target for Tango Therapeutics Inc. (NASDAQ:TNGX) on March 11th. It slightly adjusted the target to $20 from $19 and kept an Outperform rating on the stock. Mizuho’s coverage came after the precision oncology company reported its earnings for the fourth quarter and full year 2025. The results saw Tango Therapeutics Inc. (NASDAQ:TNGX) post $343 million in cash and outline that it expected to have runway beyond 2028. The firm also outlined that it was on track to start a study for pancreatic cancer treatment and added that it had entered into an agreement for evaluating a molecular glue in a clinical trial.

Tango Therapeutics' (TNGX) Sees Cautious Analyst Optimism Following Earnings

Wedbush also discussed Tango Therapeutics Inc. (NASDAQ:TNGX)’s shares in March. It raised the share price target to $19 from $15 and kept an Outperform rating on the stock. The financial firm outlined that it expected Tango Therapeutics Inc. (NASDAQ:TNGX)’s vopimetostat treatment for pancreatic cancer to enter its first major study in 2026.

Tango Therapeutics Inc. (NASDAQ:TNGX) is a biotechnology company focusing on cancer treatments. It is headquartered in Boston, Massachusetts.

While we acknowledge the risk and potential of TNGX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TNGX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None.  Follow Insider Monkey on Google News.